Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010) - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Treatment Approaches and Clinical Outcomes for Relapsed/Refractory Multiple Myeloma in Asia: A Multicenter Asian Myeloma Network Study (AMN010)

  • By

  • Melinda SY Tan

  • Kye Ling Wong

  • Cinnie Soekojo

  • Chandramouli Nagarajan

  • Sarah Burkhill

  • Xinhua Li

  • Ho-Jin Shin

  • Jong Heon Jung

  • Yeung-Chul Mun

  • Ho-Young Yhim

  • Jae Hoon Lee

  • Ling Cao

  • Tadao Ishida

  • Chihiro Shimazaki

  • Makoto Sasaki

  • Hiroyuki Takamatsu

  • Shinsuke Iida

  • Hirono Iriuchishima

  • Shuji Ozaki

  • Karen Tang

  • Jeffrey Huang

  • Jerry Teng

  • Cheng-Shyong Chang

  • Changki Min

  • Wenming Chen

  • Hiroshi Handa

  • Kihyun Kim

  • Priti Bahety

  • Juan Du

  • Wee Joo Chng

  • November 11, 2026

Share

Clinical Scorecard: Treatment Approaches and Clinical Outcomes for Relapsed/Refractory Multiple Myeloma in Asia: AMN010

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: Treatment Approaches and Clinical Outcomes for Relapsed/Refractory Multiple Myeloma in Asia
Key MechanismsGreater refractoriness across drug classes was associated with poorer outcomes; triple-class refractory disease had the worst outcomes.
Target PopulationPopulation described in the source article.
Care SettingCare setting described in the source article.

Key Highlights

  • Treatment patterns varied substantially: 75 regimens were recorded in second line, 79 in third line, and 52 in fourth line.
  • Triplet regimens were the leading strategy at each treatment line; monotherapy was most common in fourth line.
  • Outcomes worsened with successive treatment lines: median PFS was 16.1 months in second line, 9.1 months in third line, and 5.2 months in fourth line.
  • Overall response rate declined from 71.6% in second line to 43.6% in fourth line.
  • Triple-class refractory patients had the poorest outcomes; median PFS was 6.1, 8.1, and 3.8 months in second-, third-, and fourth-line settings, respectively.

Guideline-Based Recommendations

Diagnosis

    Management

    • The study reports substantial treatment heterogeneity and no definitive standard of care across the treatment lines examined.
    • The authors state that treatment selection reflected differences in access and reimbursement predominantly, rather than intrinsic biological variation among populations.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        The cohort included 626 patients receiving second-line, 341 receiving third-line, and 156 receiving fourth-line therapy. Median ages were 64, 63, and 61 years, respectively.

        Regimen use differed across countries and regions. Mainland China favored triplet- and quadruplet-based regimens; Korea more often used doublets in third line and monotherapy in fourth line; Japan primarily incorporated anti-SLAMF7-based regimens.

        Clinical Best Practices

          Related Resources & Content

            Original Source(s)

            Real-world treatment patterns and clinical outcomes in relapsed/refractory multiple myeloma across Asia: a multicenter Asian Myeloma Network study (AMN010)

            • by Melinda SY Tan, Kye Ling Wong, Cinnie Soekojo, Chandramouli Nagarajan, Sarah Burkhill, Xinhua Li, Ho-Jin Shin, Jong Heon Jung, Yeung-Chul Mun, Ho-Young Yhim, Jae Hoon Lee, Ling Cao, Tadao Ishida, Chihiro Shimazaki, Makoto Sasaki, Hiroyuki Takamatsu, Shinsuke Iida, Hirono Iriuchishima, Shuji Ozaki, Karen Tang, Jeffrey Huang, Jerry Teng, Cheng-Shyong Chang, Changki Min, Wenming Chen, Hiroshi Handa, Kihyun Kim, Priti Bahety, Juan Du, Wee Joo Chng

            • November 11, 2026

            Related Content

            Comparison of Trial-Collected and Parent-Reported Race and Ethnicity in a Children’s Oncology Group Trial

            What Your Patients Need to Know for Medicare Open Enrollment

            The annual Medicare open enrollment period runs October 15 to December 7 this year, giving adults ages 65 and older the opportunity to review and possibly change their healthcare coverage.

            • by

            • November 5, 2026

            • 2 min
            The first attempts to transplant bone marrow—tribute to Jan Raszek-Rosenbusch and Franciszek Groër.